Fleury SA (FLRYY)

Overall impact
A (87)

Commentary

Fleury SA is a leader for overall positive impact. With an 'A' rating of 86.9 for overall impact (98th percentile compared to all companies), Fleury SA ranks 2nd out of 71 industry peers, behind COMPASS Pathways, and ahead of ModivCare, Ontrak, Hanger and 66 others. On top material causes for Fleury SA's industry (Healthcare Providers), Fleury SA performs well in No Violence Against Women (91.2 score), Improved Mental Health (95.8), Child and Maternal Health (95.0) and 16 other causes where it received an 'A' score. Fleury SA did not receive a 'D' or 'F' rating on any cause.
Impact
Cause FLRYY
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1926
Employees
27,000
Sector
Health Care
Industry
Health Care Providers & Services
Sub-industry
Health Care Services
SASB industry
Health Care Delivery
Headquarters
São Paulo, Brazil
Share classes
FLRYY
ADR
Description
Fleury S.A., together with its subsidiaries, provides medical services in the diagnostic, treatment, clinical analysis, health management, medical care, orthopedics, and ophthalmology areas in Brazil. The company operates through three segments: Diagnostic Medicine, Integrated Medicine, and Dental. It provides laboratory and imaging tests, genomics, health management and platform, diagnostic information, check-up and reference laboratory, clinic day, infusion center, orthopedics and ophthalmology, dental imaging tests, and diagnostic imaging services. The company also offers Saúde I, a digital healthcare platform that provides services, including scheduling and performing teleconsultations, and face-to-face consultations. This platform also allows users to schedule and access diagnostic test results, manage electronic medical records, and self-manage health issues. It operates customer service units and hospital-based units under various brand names, including Fleury, Felippe Mattoso, Labs a+, Diagnoson a+, Papaiz, Serdil, LAFE, Instituto de Radiologia de Natal, Centro de Patologia Clínica, Diagmax, Santécorp, a+SP, CIP, Saha, Moacir Cunha, Vita, e Campana, Methodos, Pretti, Bioclinico, a+PE, Marcelo Magalhaes, Inlab, Weinmann, a+, a+BA, IRN, CPC, and a+PI. The company was founded in 1926 and is headquartered in São Paulo, Brazil.
Material causes
Ethos considers the following causes material for Fleury SA, based on its industry sub-industry Health Care Services. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.